Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS‐441524 in patients with COVID‐19: A limited case series

Remdesivir, an antiviral agent for the treatment of coronavirus disease 2019 (COVID‐19), is metabolized intracellularly, with these metabolites eliminated predominantly in urine. Because of a lack of safety and pharmacokinetic (PK) data, remdesivir is not currently recommended for patients with esti...

Descripción completa

Detalles Bibliográficos
Autores principales: Choe, Pyoeng Gyun, Jeong, Sae Im, Kang, Chang Kyung, Yang, Liju, Lee, SeungHwan, Cho, Joo‐Youn, Han, Seung Seok, Kim, Dong Ki, Lee, Sang Min, Park, Wan Beom, Oh, Myoung‐don, Kim, Nam Joong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652615/
https://www.ncbi.nlm.nih.gov/pubmed/34761554
http://dx.doi.org/10.1111/cts.13194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652615/
https://www.ncbi.nlm.nih.gov/pubmed/34761554
http://dx.doi.org/10.1111/cts.13194

Ejemplares similares